Warfarin treatment quality is consistently high in both anticoagulation clinics and primary care setting in Sweden

Thrombosis Research

Volumn 136, Issue 2, 2015, Pages 216-220

  Björck, Fredrik ^a   Sandén, Per ^a   Renlund, Henrik ^b   Svensson, Peter J ^c   Själander, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

anticoagulation; anticoagulation clinic; complications; primary care; TTR; warfarin

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULATION; ANTICOAGULATION CLINIC; ARTERIAL THROMBOEMBOLISM; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CENTRALIZATION; DIRECT CURRENT; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH CENTER; HEART INFARCTION; HOSPITAL; HUMAN; INFORMATION; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PRIMARY HEALTH CARE; PRIMARY HEALTH CARE CENTER; PRIORITY JOURNAL; PROPENSITY SCORE; REGISTER; RISK; SWEDEN; THROMBOEMBOLISM; THROMBOSIS; VENOUS THROMBOEMBOLISM; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; FEMALE; HUMANS; MALE; PRIMARY HEALTH CARE; SWEDEN; TREATMENT OUTCOME; WARFARIN;

EID: 84938557634     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.04.016     Document Type: Article

References (23)

1. The National Board of Health and Welfare (Socialstyrelsen) web site http://www.socialstyrelsen.se/statistik/statistikdatabas/lakemedel [Accessed December 10, 2014]
2. Statistics Sweden (Statistiska centralbyrån) web site http://www.scb.se [Accessed December 14, 2014]
3. D.W. Barritt, and S.C. Jordan Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial Lancet 1 1960 1309 1312
4. L. Ericson, L. Bergfeldt, and I. Björholt Atrial fibrillation: the cost of illness in Sweden Eur J Health Econ 12 2011 479 487
5. Auricula [Auricula årsrapport 2012] Auricula Annual Report 2012 2014 UCR, Uppsala Clinical Research Center [ http://www.ucr.uu.se/auricula/index.php/arsrapporter. Accessed August 23, 2014]
6. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867
7. The Medical Produtcs Agency (Läkemedelsverket) (Inrapporterade biverkningar 2012 från hälso- och sjukvården samt allmänheten) web site 2014 [ http://www.lakemedelsverket.se/upload/nyheter/2013/arsrapport-2012-biverkningar-2013-04-17.pdf. Accessed November 17, 2014]
8. J. Wallvik, A. Själander, L. Johansson, O. Bjuhr, and J.H. Jansson Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics Scand J Prim Health Care 25 2007 123 128
9. E.M. Hylek Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors Semin Vasc Med 3 2003 271 278
10. A. Själander, G. Engström, E. Berntorp, and P. Svensson Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population J Intern Med 254 2003 434 438
11. F.R. Rosendaal, S.C. Cannegieter, F.J. van der Meer, and E. Briët A method to determine the optimal intensity of oral anticoagulant therapy Thromb Haemost 69 1993 236 239
12. S.J. Connolly, J. Pogue, J. Eikelboom, G. Flaker, P. Commerford, M.G. Franzosi, and et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range Circulation 118 2008 2029 2037
13. L. Wallentin, S. Yusuf, M.D. Ezekowitz, M. Alings, M. Flather, M.G. Franzosi, and et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial Lancet 376 2010 975 983
14. M. Wieloch, A. Själander, V. Frykman, M. Rosenqvist, N. Eriksson, and P.J. Svensson Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA Eur Heart J 32 2011 2282 2289
15. B. Grzymala-Lubanski, S. Sjalander, H. Renlund, P.J. Svensson, and A. Sjalander Computer aided warfarin dosing in the Swedish national quality registry AuriculA - Algorithmic suggestions are performing better than manually changed doses Thromb Res 131 2013 130 134
16. I. Dimberg, B. Grzymala-Lubanski, A. Hagerfelth, M. Rosenqvist, P. Svensson, and A. Sjalander Computerised assistance for warfarin dosage-effects on treatment quality Eur J Intern Med 23 2012 742 744
17. Swedish National Patient Register The National Board of Health and Welfare (Socialstyrelsen) web site http://www.socialstyrelsen.se/register/halsodataregister/patientregistret/inenglish [Accessed October 10, 2014]
18. S. Schulman, R.J. Beyth, C. Kearon, M.N. Levine, and American College of Chest P Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 257S 298S
19. S. Schulman, and C. Kearon Haemostasis SoCoAotSaSCotISoTa. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 2005 692 694
20. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, and et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
21. W.L. Baker, D.A. Cios, S.D. Sander, and C.I. Coleman Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States J Manag Care Pharm 15 2009 244 252
22. S.Y. Han, S.T. Palmeri, S.H. Broderick, V. Hasselblad, D. Rendall, S. Stevens, and et al. Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting J Electrocardiol 46 2013 45 50
23. J.F. Ludvigsson, E. Andersson, A. Ekbom, M. Feychting, J.L. Kim, C. Reuterwall, and et al. External review and validation of the Swedish national inpatient register BMC Public Health 11 2011 450